November 12, 2014

Cologuard® wins Popular Science Magazine's "Best of What's New" Award

Exact Sciences Corp. (NASDAQ: EXAS) announced Cologuard has received a 2014 "Best of What's New" award from Popular Science.

Cologuard is the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer. Approved by the FDA in August, Cologuard detects the presence of cancer and precancer by analyzing both DNA and blood in the stool.

"Exact Sciences is honored to receive this recognition from the editors of Popular Science," said Kevin Conroy, Chairman and CEO of Exact Sciences. "The 'Best of What's New' list recognizes the groundbreaking potential of Cologuard to improve the colon cancer screening rates and enable survival from a disease that is often considered the most preventable, yet least prevented cancer due to the lack of patient compliance with screening."

Colorectal cancer is highly treatable with early detection through screening. However, 23 million Americans between 50 and 75 are not getting screened as recommended and, as a result, colorectal cancer remains the second-leading cancer killer in the United States. For those whose cancer is detected at an earlier stage, the five-year survival rate can be greater than 90 percent.

Read the full announcement.